(Q36080770)

12 August 2017

Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers (English)

1 reference

12 August 2017

1 reference

1 reference

Cowie FJ

1

1 reference

12 August 2017

Pinkerton CR

2

1 reference

12 August 2017

Phillips M

3

1 reference

12 August 2017

Dick G

4

1 reference

12 August 2017

Judson I

5

1 reference

12 August 2017

McCarthy PT

6

1 reference

12 August 2017

Flanagan RJ

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 1995

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

71

1 reference

12 August 2017

4

1 reference

12 August 2017

877-881

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1995.169

12 August 2017

0 references

cites work

Multidrug resistance in cancers of childhood: clinical relevance and circumvention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Clinical Pharmacokinetics of Verapamil

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Phase I and pharmacokinetic study of D-verapamil and doxorubicin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033743

D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro

11 July 2018

1 reference

12 December 2020

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

12 December 2020

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration

1 reference

12 December 2020

Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug

1 reference

12 December 2020

Phase I study of vinblastine and verapamil given by concurrent iv infusion

1 reference

12 December 2020

Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1995.169

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

7710958

1 reference